- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Nina Chavez, MBA, FACMPE: Biosimilars and Patient Out-of-Pocket Costs
Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd, discusses the role that biosimilars have to play in reducing patients’ out-of-pocket costs in cancer care.
Transcript
You know, anything that can decrease the cost to the patient is the best thing for the patient.
We have financial counselors, we have a lot of copay cards, we have a lot of drug assistance, drug replacement. We as a practice work very hard to get therapies to the patients that they cannot afford. And so, if there's a way that these biosimilars coming into the market can not only lower the total cost of care, but they can lower the patients’ out-of-pocket and that stress and anxiety that the patient has, I think that's fantastic.
I don't know how it will play out because it's so new, and right now, like I said, they're kind of marketing like the brand; they're not that much cheaper. They don't want to disrupt [average selling price, ASP]; it's more about, “we’ll give you a contract to use all of our stuff, including our biosimilar, instead of using this other guy’s, right?”
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
